Katherine E. Fleming-Dutra
Impact in
- Applied Microbiology and Biotechnology top 0.05%
- Antibiotic Use and Resistance
- Infectious Diseases top 0.5%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
Papers in
- Epidemiology 52
- Pneumonia and Respiratory Infections 43
- Respiratory viral infections research 23
-
- Antibiotic Use and Resistance 43
- Co-authors
- Lauri A. Hicks (37 shared papers)Rebecca M. Roberts (6 shared papers)Adam L. Hersh (22 shared papers)Guillermo V. Sanchez (4 shared papers)Tamara Pilishvili (6 shared papers)Laura King (16 shared papers)Amadea Britton (11 shared papers)Emily N. Ussery (1 shared paper)
- Journals
- Open Forum Infectious Diseases (18 papers)MMWR Morbidity and Mortality Weekly Report (17 papers)The Pediatric Infectious Disease Journal (11 papers)Clinical Infectious Diseases (10 papers)PEDIATRICS (7 papers)
- Partner nations
- United StatesUnited KingdomAustralia
In The Last Decade
Katherine E. Fleming-Dutra
120 papers receiving 5.0k citations
Katherine E. Fleming-Dutra's Hit Papers
Peers
Comparison fields: 5 of 165
- Applied Microbiology and Biotechnology 1.1k
- Infectious Diseases 2.0k
- Modeling and Simulation 313
- Health 535
- Epidemiology 1.9k
Countries citing papers authored by Katherine E. Fleming-Dutra
This map shows the geographic impact of Katherine E. Fleming-Dutra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine E. Fleming-Dutra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine E. Fleming-Dutra more than expected).
Fields of papers citing papers by Katherine E. Fleming-Dutra
This network shows the impact of papers produced by Katherine E. Fleming-Dutra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine E. Fleming-Dutra. The network helps show where Katherine E. Fleming-Dutra may publish in the future.
Co-authors
The 25 scholars most cited alongside Katherine E. Fleming-Dutra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 123 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020 Hit paper breakdown → | 2020 | 992 |
| 2 | Core Elements of Outpatient Antibiotic Stewardship Hit paper breakdown → | 2016 | 425 |
| 3 | Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants Hit paper breakdown → | 2022 | 403 |
| 4 | Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 Hit paper breakdown → | 2023 | 171 |
| 5 | 2019 | 166 | |
| 6 | Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 Hit paper breakdown → | 2023 | 144 |
| 7 | 2018 | 123 | |
| 8 | 2019 | 119 | |
| 9 | 2022 | 88 | |
| 10 | 2020 | 88 | |
| 11 | 2022 | 88 | |
| 12 | 2018 | 86 | |
| 13 | 2022 | 86 | |
| 14 | 2020 | 84 | |
| 15 | 2013 | 83 | |
| 16 | Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024 Hit paper breakdown → | 2024 | 80 |
| 17 | 2016 | 78 | |
| 18 | 2013 | 77 | |
| 19 | 2013 | 77 | |
| 20 | Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023 Hit paper breakdown → | 2023 | 76 |
About Katherine E. Fleming-Dutra
Katherine E. Fleming-Dutra is a scholar working on Epidemiology, Applied Microbiology and Biotechnology, Infectious Diseases, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health, having authored 123 papers that have together received 5.3k indexed citations. Recurring topics across this work include Pneumonia and Respiratory Infections (43 papers), Antibiotic Use and Resistance (43 papers), Respiratory viral infections research (23 papers), SARS-CoV-2 and COVID-19 Research (19 papers), Respiratory and Cough-Related Research (16 papers), Vaccine Coverage and Hesitancy (12 papers), Building Energy and Comfort Optimization (11 papers) and Patient Satisfaction in Healthcare (10 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (1.1k citations), Infectious Diseases (2.0k citations), Modeling and Simulation (313 citations), Health (535 citations) and Epidemiology (1.9k citations). Katherine E. Fleming-Dutra has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Lauri A. Hicks, Rebecca M. Roberts, Adam L. Hersh, Guillermo V. Sanchez, Tamara Pilishvili, Laura King, Amadea Britton, Emily N. Ussery, Aron J. Hall and Katherine Roguski. Their work appears in journals such as Open Forum Infectious Diseases, MMWR Morbidity and Mortality Weekly Report, The Pediatric Infectious Disease Journal, Clinical Infectious Diseases and PEDIATRICS.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.